EXTH-07. MUTANT ISOCITRATE DEHYDROGENASE 1 (IDH1) INHIBITOR SYC-435 SYNERGISTICALLY PROLONGS ANIMAL SURVIVAL WITH STANDARD THERAPIES IN PATIENT-DERIVED IDH1 MUTANT GLIOMA XENOGRAFT MOUSE MODELS
Mari Kogiso,Lin Qi,Huiyuan Zhang,Frank Braun,Yuchen Du,Yulun Huang,Holly Lindsay,Sibo Zhao,Sarah Injac,Zhen Liu,Patricia Baxter,Jack Su,Laszlo Perlaky,D Will Parsons,Murali Chintagumpala,Adekunle Adesina,Jialiang Wang,Yongcheng Song,Xiao-Nan Li
DOI: https://doi.org/10.1093/neuonc/nox168.303
2017-01-01
Neuro-Oncology
Abstract:Glioblastoma (GBM) is the most common primary brain tumor with a median survival of 14.5 months, despite maximal therapy consisting of surgical resection, radiation and temozolomide (TMZ).Genetic profiling has shown an average of three driver mutations localized to the p53, Rb and receptor tyrosine kinase networks, to be responsible for selective growth advantage of GBM.However, single cells from the same tumor often have different combinations of these driver mutations.This intra-tumoral heterogeneity is a major cause of treatment failure and disease recurrence.microRNA-34a (miR-34a) modulates the expression of multiple genes in all three deregulated GBM networks and therefore has the potential to counteract intra-tumor heterogeneity, thereby optimizing treatment.Transfection of miR-34a as monotherapy significantly reduced proliferation in multiple established GBM cell lines (A172, LN229, T98G and U251) and three primary patient-derived cell cultures (GBM6, GBM118 and GBM 126).The latter cultures were respectively characterized as classical, mesenchymal and proneural, based on mRNA expression analysis.In our in vitro experiments and the literature, T98G and U251 cell lines are resistant to TMZ, while A172 and LN229 are sensitive.miR-34a sensitized TMZ resistant, TMZ sensitive and primary cell cultures to TMZ.As an in vitro model of TMZ resistance, we cultured cells in TMZ for two weeks and created two stable TMZ resistant lines from A172 and LN229 which could be sensitized to TMZ after miR-34a treatment.Mechanistic studies indicate that miR-34a synergizes with TMZ due, in part, to direct inhibition of Bcl2 protein expression by miR-34a.Efforts also are ongoing to deliver miR-34a to orthotopic tumors using different types of nanoparticles.In conclusion, miR-34a is a promising novel therapeutic that inhibits proliferation and synergizes with TMZ in multiple GBM established cell lines and primary cultures.